GlassScriptPhysician profile
George B Leber
NPI 1275636060
$5,252.89
in general payments reported to CMS, 2019-2025
39 companies · $785 in 2025
The $785 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $358 · 2021: $306 · 2022: $748 · 2023: $1,123 · 2024: $1,118 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,964 · Education: $61.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,964.34 |
| Education | $61.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $982.40 | 2019-2025 | |
| Pfizer INC. | $404.19 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $360.61 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $327.34 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $322.44 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $290.63 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $238.83 | 2019-2025 | Farxiga, Atacand, Wainua |
| Cvrx, INC. | $213.15 | 2022-2024 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $180.71 | 2019-2025 | Amvuttra, Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.93 | 2019-2025 | Jardiance |
| Heartflow, INC. | $158.71 | 2024-2025 | |
| Baxter Healthcare | $157.59 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Novo Nordisk INC | $126.11 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $109.49 | 2023-2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $108.32 | 2023-2024 | Inpefa |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Leber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.